secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001213900-25-013204
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed Q2 net loss $2.6M, cash burn continues; BayMedica profitable amid revenue drop
--------------------------------------------------------------------------------

- Q2 net loss $2.6M vs $1.5M YoY; BayMedica revenue $1.1M (-10% YoY).
- Cash $3.5M at Dec 31, 2024; raised $2.9M in Jan 2025; expects funding through Q2 2025.
- INM-901 Alzheimer's preclinical data reduced neuroinflammatory markers; INM-089 IVT formulation for dry AMD.
- Director Janet Grove resigned after withheld votes at Dec 2024 AGM; board to find replacement.
- BayMedica net income $0.23M (+189%) despite revenue drop due to cost cuts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025013204/0001213900-25-013204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025013204/ea0230951-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-013204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer